secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zeo ScientifiX, Inc. (ZEOX)
CIK:        0001557376
Form:       8-K
Filed at:   2023-07-26T23:59:59+00:00
Accession:  0001829126-23-004890
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Organicell reports no safety events in Phase 1/2a studies of Zofin; plans Phase 2 in 2024
--------------------------------------------------------------------------------

- No therapy-related safety events or significant adverse events across three Phase 1/2a studies with over 20 Zofin-treated patients.
- Studies include knee osteoarthritis, moderate-to-severe COVID-19, and long-haul COVID-19 (expected completion October 2023).
- Company plans to initiate larger Phase 2 studies for multiple chronic conditions in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1557376/000182912623004890/0001829126-23-004890-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1557376/000182912623004890/organicellregen_8k.htm
  HTML page:      https://secwatch.observer/filing/0001829126-23-004890

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer